Kim Andy Jeesu, Chang Janet Ya-An, Shi Liheng, Chang Richard Cheng-An, Ko Michael Lee, Ko Gladys Yi-Ping
Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States.
Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States.
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):106-118. doi: 10.1167/iovs.16-20691.
The purpose of this study was to determine the effects of metformin on dysfunctional retinas in obesity-induced type 2 diabetic mice.
A high-fat diet (HFD)-induced diabetic mouse model (C57BL/6J) was used in this study. After 2 months of the HFD regimen, HFD mice were given daily metformin through oral gavage. Body weights, glucose tolerance, and retinal light responses were monitored regularly. Fluorescein angiography (FA) was used to assess changes in retinal vasculature. Ocular tissues (retina, vitreous, and lens) were harvested and analyzed for molecular changes as determined by immunofluorescent staining, Western blot analysis, and cytokine profiling.
Starting 1 month after the diet regimen, mice fed the HFD had mildly compromised retinal light responses as measured by electroretinography (ERG), which worsened over time compared to that in the control. In HFD mice treated with metformin, systemic glucose levels reverted back to normal, and their weight gain slowed. Metformin reversed HFD-induced changes in phosphorylated protein kinase B (pAKT), extracellular signal-regulated kinase (pERK), and 5'AMP-activated protein kinase (pAMPK) in the retina. However, metformin treatments for 3 months did not restore the retinal light responses nor lessen the HFD-induced retinal neovascularization, even though it did reduce intraocular inflammation.
Although metformin was able to reverse systemic changes induced by HFD, it was not able to restore HFD-caused retinal light responses or deter neovascularization.
本研究旨在确定二甲双胍对肥胖诱导的2型糖尿病小鼠功能失调视网膜的影响。
本研究使用高脂饮食(HFD)诱导的糖尿病小鼠模型(C57BL/6J)。在高脂饮食方案实施2个月后,通过口服灌胃给予高脂饮食小鼠每日二甲双胍。定期监测体重、葡萄糖耐量和视网膜光反应。使用荧光素血管造影(FA)评估视网膜血管系统的变化。收集眼组织(视网膜、玻璃体和晶状体),并通过免疫荧光染色、蛋白质印迹分析和细胞因子谱分析来确定分子变化。
从饮食方案开始1个月后,通过视网膜电图(ERG)测量,喂食高脂饮食的小鼠视网膜光反应略有受损,与对照组相比,随着时间的推移情况恶化。在用二甲双胍治疗的高脂饮食小鼠中,全身血糖水平恢复正常,体重增加减缓。二甲双胍逆转了高脂饮食诱导的视网膜中磷酸化蛋白激酶B(pAKT)、细胞外信号调节激酶(pERK)和5'AMP激活蛋白激酶(pAMPK)的变化。然而,即使二甲双胍治疗3个月确实减轻了眼内炎症,但它并未恢复视网膜光反应,也未减轻高脂饮食诱导的视网膜新生血管形成。
尽管二甲双胍能够逆转高脂饮食引起的全身变化,但它无法恢复高脂饮食导致的视网膜光反应或阻止新生血管形成。